An Open Label Single Arm Clinical Study to Evaluate the Safety and Efficacy of HQMZ111831 as a Lactation Support in Lactating Mothers - Quista_Momz

The Himalaya Drug Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Lactating mothers aged >=18 years <=40 years and has completed 48 hours of post-partum period, who are planning at least three months of breast feeding to the infant
•Mother confirms her intention to breastfeed and refrains from joining work outside during the study period.
•Mother is non-smoker and non-alcoholic.
•Infant is judged to be in good health.
•Mothers planning only with the conventional breast feeding method and not intending to use breast pump.
•Mother confirms her intention to breastfeed and refrains from taking any other
•supplement or galactogogues during the study period.

•Mother has any anatomical defect in the breast or nipple like mastectomy, retracted nipples which may interfere with the normal breast feeding.
•Mother is allergic or intolerant to any ingredient found in the study product.
•An adverse maternal, fetal or infant medical history that has potential effects on child growth and or development.
•Mother and or newborn infant has major illness that requires intensive care admission.
•Infant has major congenital anomaly.
•Infant with cleft lip, palate which may impair breast feeding.

发起方